kabutan

KYORIN Pharma, 52% Decrease in Ordinary Profit for The Current Fiscal Year, Increased Previous Year's Dividend by 5 yen, Plan to Continue the 57 yen Policy This Fiscal Year as Well

Mon May 12, 2025 3:30 pm JST Earnings

4569 KYORIN Pharmaceutical Co.,Ltd. 【J-GAAP】

Earnings Report

KYORIN Pharmaceutical Co.,Ltd. <4569> [TSE Prime] announced its financial results after the market closed on May 12th (15:30). The consolidated ordinary profit for the fiscal year ending March 2025 expanded 93.8% from the previous period to 13.2 billion yen. However, for the fiscal year ending March 2026 is also bleak, with an expected significant drop by 52.3% from the previous period to 6.3 billion yen.

At the same time, the company increased the annual dividend for the previous term from 52 yen to 57 yen (compared to 52 yen in the prior term), and has decided to continue with a dividend of 57 yen for the current term as well.

In the most recent three-month period, from January to March (4Q), the consolidated ordinary profit surged 6.6 times that of the same period last year, reaching 9.46 billion yen. The operating profit margin drastically improved from 4.4% in the same period last year to 23.2%.

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 113,270 5,123 5,827 4,723 82.4 52 May 11, 2023 J-GAAP
Mar, 2024 119,532 6,234 6,822 5,475 95.4 52 May 10, 2024 J-GAAP
Mar, 2025 130,087 12,567 13,219 9,086 158.2 57 May 12, 2025 J-GAAP
YoY +8.8% +101.6% +93.8% +66.0% +65.8%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 130,000 12,500 13,200 9,000 156.7 52 Apr 23, 2025 J-GAAP
Mar, 2025 Results 130,087 12,567 13,219 9,086 158.2 57 May 12, 2025 J-GAAP
Revision Rate +0.1% +0.5% +0.1% +1.0% +1.0%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 55,139 1,549 2,050 1,255 21.9 20 Nov 7, 2024 J-GAAP
Apr - Sep, 2025 Guidance 57,400 1,700 1,800 1,400 24.4 20 May 12, 2025 J-GAAP
YoY +4.1% +9.7% -12.2% +11.6% +11.5%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 119,532 6,234 6,822 5,475 95.4 52 May 10, 2024 J-GAAP
Mar, 2025 130,087 12,567 13,219 9,086 158.2 57 May 12, 2025 J-GAAP
Mar, 2026 Guidance 127,000 6,100 6,300 4,800 83.6 57 May 12, 2025 J-GAAP
YoY -2.4% -51.5% -52.3% -47.2% -47.2%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 32,265 1,431 1,431 1,326 23.1 4.4 May 10, 2024 J-GAAP
Apr - Jun, 2024 28,419 1,150 1,417 885 15.4 4.0 Jul 31, 2024 J-GAAP
Jul - Sep, 2024 26,720 399 633 370 6.4 1.5 Nov 7, 2024 J-GAAP
Oct - Dec, 2024 34,147 1,566 1,703 1,184 20.6 4.6 Feb 5, 2025 J-GAAP
Jan - Mar, 2025 40,801 9,452 9,466 6,647 115.7 23.2 May 12, 2025 J-GAAP
YoY +26.5% +560.5% +561.5% +401.3% +400.7%

Related Articles